Annji Pharmaceutical Co (ROCO:7754) Change In Receivables: NT$0.83 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7754 Annji Pharmaceutical Co Ltd ROCO:7754
18 GF Score
Price NT$66.10
! 5 Warning Signs
View Full Analysis

What is Annji Pharmaceutical Co Change In Receivables?

Annji Pharmaceutical Co ROCO:7754 +5.90% 18 Change In Receivables is NT$0.83 Mil as of Jun. 2026. GuruFocus rates ROCO:7754 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Annji Pharmaceutical Co's change in receivables for the quarter that ended in Jun. 2026 was NT$-0.07 Mil. It means Annji Pharmaceutical Co's Accounts Receivable increased by NT$0.07 Mil from Dec. 2025 to Jun. 2026 .

Annji Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2025 was NT$0.25 Mil. It means Annji Pharmaceutical Co's Accounts Receivable declined by NT$0.25 Mil from Dec. 2024 to Dec. 2025 .

Annji Pharmaceutical Co's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$0.08 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Annji Pharmaceutical Co's Days Sales Outstanding for the six months ended in Jun. 2026 was 26.70.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Annji Pharmaceutical Co's liquidation value for the six months ended in Jun. 2026 was NT$199.60 Mil.

Annji Pharmaceutical Co  (ROCO:7754) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Annji Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.079/0.54*91
=26.70

2. In Ben Graham's calculation of liquidation value, Annji Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Annji Pharmaceutical Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=460.265-270.997+0.75 * 0.079+0.5 * 20.536
=199.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co Change In Receivables Related Terms

Annji Pharmaceutical Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Annji Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co Change In Receivables Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.56 -0.02 -0.87 1.17 0.25

Annji Pharmaceutical Co Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial 0.81 0.36 -0.65 0.90 -0.07
ROCO:7754
18GF Score
Annji Pharmaceutical Co Ltd ROCO:7754
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annji Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$0.83 Mil mean?
Annji Pharmaceutical Co (ROCO:7754) has a Change In Receivables of NT$0.83 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Annji Pharmaceutical Co and its competitors.
Is Annji Pharmaceutical Co's Change In Receivables too high?
Annji Pharmaceutical Co's current Change In Receivables is NT$0.83 Mil. Overall, Annji Pharmaceutical Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's Change In Receivables compare to VRTX and REGN?
Annji Pharmaceutical Co's Change In Receivables of NT$0.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current Change In Receivables is NT$0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current Change In Receivables of NT$0.83 Mil. The current Change In Receivables is NT$0.83 Mil. Annji Pharmaceutical Co's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current Change In Receivables is NT$0.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annji Pharmaceutical Co Business Description

Address Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
18GF Score

Get the complete analysis for ROCO:7754

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$66.10
Price